Levalbuterol Articles
US patent settlements of Xopenex and Lidoderm
30 May 2012
Sepracor's 1st-qtr revenues jump 3%
5 May 2009
FDA says CFC inhalers will cease end 2008
9 June 2008
Nycomed licenses US rights to ciclesonide drugs to Sepracor in deal worth up to $430M
4 February 2008
USA's NIH updated asthma treatment guidelines welcomed by industry
10 September 2007
Barr confirms Xoprenex patent challenge
23 July 2007
Sepracor takes issue with CMS "bundling" of Xopenex
25 June 2007
Sepracor gets notice of ANDA on levalbuterol
19 September 2005
FDA OKs Sepracor's Xophenex metered-dose inhaler
21 March 2005
Sepracor files NDA for Xopenex HFA MDI
24 May 2004
Sepracor amends Xopenex promotion deal with Ross
29 March 2004
Sepracor's 4th-qtr Xopenex revenues leap 53%
26 January 2004
Sepracor improves position in 2002
10 February 2003
Sepracor gets OK for Xopenox in children
11 February 2002
Strong Q4 revenue rise at Sepracor
28 January 2002
Xopenex filed for use in younger children
5 April 2001
Sepracor files NDA for norastemizole
13 March 2001
New form of levalbuterol clears Ph II study
18 January 2001
Busy year for NCEs as major new compound classes launched
6 January 2000
Second FDA rebuke for Sepracor over Xopenox
15 June 1999
Sepracor falls on Xopenox rebuke
21 April 1999
Levalbuterol Nears Approval In USA
7 July 1998
Sepracor's Levalbuterol Superior To Racemate
28 April 1998
FDA Accepts Sepracor's Levalbuterol
4 September 1997
Sepracor's Norastemizole "Effective" In Phase II
31 July 1997
Sepracor Submits NDA For Levalbuterol
9 July 1997
Showing 1-32 of 32 articles
- 1
- Takeda debuts three new diabetes drugs, Nesina, Kazano and Oseni, in USA
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- It's official: "obesity is a disease," says AMA
- Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD
